Personalis, Inc. (NASDAQ: PSNL) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.09 | Insider Own | 28.21% | Shs Outstand | 106.75M | Perf Week | 1.17% |
| Market Cap | 1.75B | Forward P/E | - | EPS next Y | -0.94 | Insider Trans | -1.71% | Shs Float | 65.77M | Perf Month | 3.73% |
| Enterprise Value | 1.57B | PEG | - | EPS next Q | -0.26 | Inst Own | - | Short Float | 12.75% | Perf Quarter | 55.60% |
| Income | -108.00M | P/S | 25.75 | EPS this Y | 1.01% | Inst Trans | - | Short Ratio | 2.01 | Perf Half Y | 128.09% |
| Sales | 68.00M | P/B | 7.45 | EPS next Y | 12.98% | ROA | -34.34% | Short Interest | 8.38M | Perf YTD | 106.03% |
| Book/sh | 2.20 | P/C | 8.22 | EPS next 5Y | - | ROE | -46.47% | 52W High | 18.89 -13.18% | Perf Year | 186.21% |
| Cash/sh | 2.00 | P/FCF | - | EPS past 3/5Y | - | ROIC | -41.78% | 52W Low | 4.96 230.65% | Perf 3Y | 1079.86% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 2.50% -2.39% | Gross Margin | 12.69% | Volatility | 2.35% 4.03% | Perf 5Y | -24.00% |
| Dividend TTM | - | EV/Sales | 23.07 | EPS Y/Y TTM | 20.44% | Oper. Margin | -164.07% | ATR (14) | 0.64 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.08 | Sales Y/Y TTM | -20.00% | Profit Margin | -153.84% | RSI (14) | 55.60 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.28 | EPS Q/Q | -30.43% | SMA20 | -2.06% | Beta | 2.29 | Target Price | 14.95 |
| Payout | 0.00% | Debt/Eq | 0.13 | Sales Q/Q | 29.41% | SMA50 | 9.52% | Rel Volume | 0.78 | Prev Close | 16.23 |
| Employees | 260 | LT Debt/Eq | 0.12 | Earnings | Nov 03 | SMA200 | 60.97% | Avg Volume | 4.08M | Price | 16.40 |
| IPO Date | Jun 20, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -13.93% 33.97% | Net Debt/EBITDA | 0.58 | Volume | 3,180,369 | Change | 1.05% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-24-26 | Reiterated | Craig-Hallum | $16 | |
| Jul-20-26 | Downgrade | Lake Street | Buy → Hold | $11 → $16 |
| Jul-20-26 | Downgrade | Needham | Buy → Hold | $17 |
| Jul-20-26 | Reiterated | BTIG | Buy | $11 → $16 |
| Jul-17-26 | Reiterated | Needham | Buy | $10 → $17 |
| May-12-26 | Reiterated | Morgan Stanley | Equal Weight | $11 → $9.00 |
| May-11-26 | Reiterated | BTIG | Buy | $6.00 → $11 |
| Jan-26-26 | Reiterated | Guggenheim | Buy | $13 |
| Nov-05-25 | Reiterated | Lake Street | Buy | $9.00 → $11 |
| Nov-05-25 | Reiterated | Needham | Buy | $5.50 → $10 |
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 68 | 70 | 85 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 61 | 54 | 58 | — | — | — | — | — | — | |
| Gross Profit | 9 | 16 | 27 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 67 | 54 | 46 | — | — | — | — | — | — | |
| Research and Development | 56 | 50 | 49 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -114 | -88 | -68 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 7 | -13 | — | — | — | — | — | — | |
| Net Income Before Taxes | -108 | -81 | -81 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -108 | -81 | -81 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -108 | -81 | -81 | — | — | — | — | — | — | |
| Net Income | -108 | -81 | -81 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.09 | -0.91 | -1.37 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.09 | -0.91 | -1.37 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.09 | -0.91 | -1.37 | — | — | — | — | — | — | |
| EBITDA | -97 | -71 | -70 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 25.32 | 10.12 | 4.01 | — | — | — | — | — | — | |
| Gross Margin | 13.24 | 22.86 | 31.76 | — | — | — | — | — | — | |
| Operating Margin | -167.65 | -125.71 | -80.00 | — | — | — | — | — | — | |
| Net Margin | -158.82 | -115.71 | -95.29 | — | — | — | — | — | — | |
| Shares Outstanding | 105 | 89 | 59 | — | — | — | — | — | — | |
| Market Capitalization | 1,722 | 708 | 341 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Chen Richard | President and CMO | Jul 15 '26 | Sale | 15.15 | 100,000 | 1,515,000 | 173,880 | Jul 15 |
| Chen Richard | President and CMO | Jul 15 '26 | Option Exercise | 2.44 | 100,000 | 244,000 | 273,880 | Jul 15 |
| Hall Christopher M | Chief Executive Officer | Jul 09 '26 | Option Exercise | 1.61 | 200,000 | 322,000 | 335,986 | Jul 09 |
| Hall Christopher M | Chief Executive Officer | Jul 09 '26 | Sale | 15.08 | 100,000 | 1,508,000 | 235,986 | Jul 09 |
| Tachibana Aaron | CFO AND COO | Jun 29 '26 | Option Exercise | 5.32 | 4,982 | 26,504 | 203,815 | Jun 29 |
| Tachibana Aaron | CFO AND COO | Jun 29 '26 | Sale | 14.00 | 4,982 | 69,748 | 198,833 | Jun 29 |
| Tachibana Aaron | CFO AND COO | Jun 26 '26 | Sale | 13.18 | 51,251 | 675,488 | 198,833 | Jun 26 |
| Tachibana Aaron | CFO AND COO | Jun 26 '26 | Option Exercise | 7.48 | 51,251 | 383,370 | 250,084 | Jun 26 |
| Hall Christopher M | Chief Executive Officer | Jun 26 '26 | Option Exercise | 1.61 | 100,000 | 161,000 | 335,986 | Jun 26 |
| Hall Christopher M | Chief Executive Officer | Jun 26 '26 | Sale | 13.15 | 100,000 | 1,315,000 | 235,986 | Jun 26 |
| Tachibana Aaron | CFO AND COO | Jun 04 '26 | Sale | 12.01 | 40,000 | 480,400 | 198,833 | Jun 05 |
| Tachibana Aaron | CFO AND COO | Jun 04 '26 | Option Exercise | 9.16 | 40,000 | 366,400 | 238,833 | Jun 05 |
| Tachibana Aaron | CFO AND COO | May 29 '26 | Option Exercise | 9.16 | 38,799 | 355,399 | 237,632 | May 29 |
| Tachibana Aaron | CFO AND COO | May 29 '26 | Sale | 11.58 | 38,799 | 449,292 | 198,833 | May 29 |
| Hall Christopher M | Chief Executive Officer | May 29 '26 | Option Exercise | 1.61 | 80,091 | 128,947 | 316,077 | May 29 |